Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

LFTD Partners Inc. LSFP OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
46/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

LFTD Partners Inc. (LSFP) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.92. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $36.9T, +39190425.1%/yr average growth. Net income is $24.9T (loss), growing at -7254392.9%/yr. Net profit margin is -67.4% (negative). Gross margin is 34.2% (-2 pp trend).

Balance sheet: total debt is $1.8T against $12.6T equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 3.04 (strong liquidity). Debt-to-assets is 9.1%. Total assets: $19.3T.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 25/100 (Fail), Health 83/100 (Pass), Moat 52/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

LSFP SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 52/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LSFP

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
LSFP: +39190425.1%/yr revenue is, -7254392.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
LSFP: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
83/100
Balance sheet LSFP: Debt-to-Equity (D/E) ratio 0.14 (conservative), Current ratio is 3.04 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
52/100
LSFP: Gross margin is 34.2% (-2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
LSFP: Net profit margin is -67.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.78-3.92
Volume1.81K
Avg Volume (30D)1.33K
Beta (1Y)-0.95
Share Statistics
EPS (TTM)-1.68
Shares Outstanding$14.82M
IPO Date2021-11-23
Employees80
Financial Highlights & Ratios
Revenue (TTM)$36.92T
Gross Profit$12.62T
EBITDA$-25.34T
Net Income$-24.87T
Operating Income$913.21B
Total Cash$1.77T
Total Debt$1.76T
Net Debt$-9.26B
Total Assets$19.27T
Price / Earnings (P/E)-2.3
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS50203G1040

Price Chart

Track all markets on TradingView
LSFP
LFTD Partners Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
3.78 52WK RANGE 3.92

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message